$2.66
−18.31%Oct 8, 2026, 12:00 UTC
Medicus Pharma provided a shareholder update marking its third anniversary and outlining its progress and potential path to long-term value.
Source:Sep 29, 2026, 11:30 UTC
Medicus Pharma submitted an optimized registrational protocol for Teverelix to the FDA for a partner-ready program in advanced prostate cancer.
Sep 21, 2026, 11:30 UTC
Medicus Pharma Ltd. announced an exclusive development focus for its SkinJect product in Gorlin syndrome following commercial, clinical and regulatory assessment.
Sep 11, 2026, 12:04 UTC
Medicus Pharma Ltd. issued 8,529,412 restricted common shares to certain officers and employees at $0.1705 per share, worth about $1.45 million, in lieu of cash bonuses under a private placement exempt from registration.
Sep 10, 2026, 11:30 UTC
Medicus Pharma published abridged final Phase 2 clinical study report results for its SkinJect D-MNA patch, identifying the 200 µg dose as the lead development dose.
Sep 8, 2026, 13:43 UTC
Medicus Pharma announced on Tuesday that it is repositioning as a precision oncology-led biotechnology company, making CD228V, a second-generation antibody-drug conjugate, its principal strategic priority.
Source:Sep 3, 2026, 12:03 UTC
Medicus Pharma Ltd. signed a Co-Development and License Agreement with Pfizer Inc., under which Pfizer granted Medicus an exclusive worldwide license to develop, manufacture and commercialize PF-08046031 (CD228V), with Medicus paying a $12.0 million upfront fee and Pfizer paying a $2.0 million development funding payment.
Aug 13, 2026, 12:52 UTC
Medicus Pharma raised about $40 million through equity and debt financing during the first half of 2026.
Source:Aug 12, 2026, 18:00 UTC
Medicus Pharma Ltd. reported financial results for the three and six months ended June 30, 2026, and provided a corporate update on its development programs.
Aug 3, 2026, 14:02 UTC
Medicus Pharma announced that its chief medical officer, Dr Faisal Mehmud, will become CEO of its UK subsidiary Antev Limited on August 30, consolidating leadership of the Teverelix clinical programme.
Source:Jul 31, 2026, 13:32 UTC
Medicus Pharma received Investigational New Drug authorization from the United Arab Emirates Department of Health – Abu Dhabi for its Phase 2a PRECISION-E2 clinical study of Teverelix in women with moderate-to-severe symptomatic endometriosis.
Source:Jul 27, 2026, 12:17 UTC
Medicus Pharma received an FDA 'Study May Proceed' letter for its NDA-enabling registrational SkinJect study in patients with Gorlin syndrome.
Jul 18, 2026, 16:45 UTC
Medicus Pharma acquired the Teverelix development programme through its purchase of UK-based Antev.
Source:Jul 18, 2026, 16:45 UTC
Medicus Pharma received Institutional Review Board approval and US FDA acceptance for the revised clinical study protocol for Teverelix.
Source:Jun 15, 2026, 11:30 UTC
Medicus Pharma submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect in Gorlin Syndrome.
Jun 8, 2026, 12:51 UTC
Medicus Pharma filed a substantial modification application through the EU Clinical Trials Information System to advance a Phase 2b study of its prostate cancer drug Teverelix.
Source:Jun 6, 2026, 15:31 UTC
Medicus Pharma filed a registration study with the US Food and Drug Administration for its SkinJect program targeting Gorlin syndrome.
Source:Jun 3, 2026, 12:00 UTC
Medicus Pharma submitted Protocol SKNJCT-005 to the FDA under its existing IND for SkinJect® registrational development for Gorlin Syndrome.